Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of icariside II in preparation of anti-melanoma medicament
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for icariside and melanoma, which is applied in the field of drug preparation and can solve the problems that the use of anti-melanoma drugs has not been reported yet.
Inactive Publication Date: 2011-05-25
AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF1 Cites 5 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, the use of icariside II in the preparation of anti-melanoma drugs has not yet been reported
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0021] Example 1 In vitro experiment of icariside II against melanoma cell lines
[0022] Materials and Methods
[0023] 1. Cell line: mouse melanoma cell line (B16), purchased from Shanghai CellBank, Chinese Academy of Sciences. Human melanoma cell lines (A375 and SK-MEL-2) were purchased from ATCC. The above cell lines were incubated in DMEM medium containing 10% fetal bovine serum at 37°C with a volume fraction of 5% CO 2 , Routine culture under fully saturated humidity conditions, replace the medium for 48 hours, when the cell growth reaches saturation, digest with 0.25% trypsin + 0.02% EDTA for passage, once every 2-3 days, the experiment uses logarithmic growth phase cells.
[0024] 2. Detection of cell proliferation:
[0025] Adjust the cell suspension concentration of B16, A375 and SK-MEL-2 cell lines to 1×10 5 / mL, added to 96-well culture plate, 100 μL per well, placed at 37°C 5% CO 2 Incubator for 24h. The old medium was sucked off, and serum-free DMEM medium...
Embodiment 2
[0037] Example 2: In vivo experiment of icariside II against melanoma
[0038] Materials and Methods
[0039] 1. Experimental animals: C57BL / 6J mice, male, 8 weeks old, raised in separate cages, 4 mice per cage. Two B16 tumor-bearing mice were male. The room temperature of the breeding environment is 20°C-25°C, the relative humidity is 50%-70%, and the light-dark cycle is 12h.
[0040] 2. Model preparation and group administration:
[0041] Two B16 tumor-bearing mice were sacrificed by cervical dislocation, and the tumor tissues were collected under aseptic conditions, chopped, ground, and sieved to prepare a tumor single-cell suspension, and the cell concentration was adjusted to 1×10 6 / ml. C57BL / 6J mice were subcutaneously inoculated with tumor single cell suspension in the right armpit, each 0.2mL (containing about 2×10 5tumor cells). On the 8th day of modeling, the C57BL / 6J mice were divided into 3 groups: tumor-bearing control group, medium-dose icariside II group,...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention belongs to the field of medicament preparation, relates to new medicinal application of icariside II, and particularly relates to application of icariside II in preparation of an anti-melanoma medicament. The icariside II is adopted for intervention experiments of mouse melanomacell strains and human melanomacell strains; by observing the inhibiting condition of the icariside II on cell proliferation, the results show that the icariside II can remarkably inhibit the proliferation of B16, A375 and SK-MEL-2 cells in vitro, obviously promote apoptosis of the cells and increase P53 proteinphosphorylation and caspace protein expression; and the icariside II can remarkably inhibit loaded B16 mouse subcutaneous transplant tumor volume. Experiment results prove that the icariside II can effectively inhibit the melanoma. The icariside II can further be used for preparing the anti-melanoma medicament by adding proper pharmaceutically-acceptable carriers.
Description
Technical field: [0001] The invention belongs to the field of medicine preparation. The invention relates to a new medical application of icariside II, in particular to the application of icariside II in the preparation of anti-melanoma drugs. Background technique: [0002] Melanoma is a common clinical tumor, often primary in the skin and mucous membranes. Observations in clinical practice show that the degree of malignancy is high and distant metastasis is prone to occur. It is not sensitive to radiotherapy and chemotherapy, and its 5-year survival rate is very low. [0003] Screening active ingredients from natural medicines is a new direction for melanoma therapy. [0004] Icariside II is present in a small amount in Epimedium Herba, and its chemical structure is as follows: [0005] [0006] Icariside II [0007] At present, there are few reports on the pharmacological activity of epimedium. Chinese patent CN200780034447.9 discloses "Application of Icariside II...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
